Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood

Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar

(2015) O. Aisiku et al.   BLOOD

Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent

(2015) Shauna L. French et al.   BLOOD REVIEWS

The class II PI 3-kinase, PI3KC2α, links platelet internal membrane structure to shear-dependent adhesive function

(2015) Jessica K. Mountford et al.   Nature Communications

Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race

(2014) L. C. Edelstein et al.   BLOOD

Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis

(2014) M. M. Mumaw et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

On World Thrombosis Day

(2014) Frits R Rosendaal et al.   LANCET

PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact

(2014) Heather M. Judge et al.   PLATELETS

Thrombin-induced platelet activation via PAR4: pivotal role for exosite II

(2014) Niklas Boknäs et al.   THROMBOSIS AND HAEMOSTASIS

Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c

(2013) Leonard C Edelstein et al.   NATURE MEDICINE

Platelet secretion is kinetically heterogeneous in an agonist-responsive manner

(2012) D. Jonnalagadda et al.   BLOOD

Thrombin generation: What have we learned?

(2012) Raed Al Dieri et al.   BLOOD REVIEWS

Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice

(2012) H Lee et al.   BRITISH JOURNAL OF PHARMACOLOGY

Platelet-targeting sensor reveals thrombin gradients within blood clots forming in microfluidic assays and in mouse

(2012) J. D. WELSH et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Vorapaxar in the Secondary Prevention of Atherothrombotic Events

(2012) David A. Morrow et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs

(2012) H. Lee et al.   THROMBOSIS AND HAEMOSTASIS

Protease-activated receptor 1 (PAR1) signalling desensitization is counteracted via PAR4 signalling in human platelets

(2011) Knut Fälker et al.   BIOCHEMICAL JOURNAL

A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia

(2011) Lacramioara Ivanciu et al.   NATURE BIOTECHNOLOGY

Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

(2011) Pierluigi Tricoci et al.   NEW ENGLAND JOURNAL OF MEDICINE

The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions

(2011) Hannah Lee et al.   THROMBOSIS AND HAEMOSTASIS

The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation

(2010) Chin-Chung Wu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

(2010) S. Goto et al.   EUROPEAN HEART JOURNAL

Deficiency of PAR4 Attenuates Cerebral Ischemia/Reperfusion Injury in Mice

(2010) Yingying Mao et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Annexin V binding to platelets is agonist, time and temperature dependent

(2010) Sofia Ramstrom et al.   PLATELETS

Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets

(2010) C.-C. Wu et al.   THROMBOSIS AND HAEMOSTASIS

Protease-activated receptors as targets for antiplatelet therapy

(2008) Justin R. Hamilton   BLOOD REVIEWS